EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 732 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... August 5, 2021 The digital shift: How are remote GP appointments affecting cancer patients? December 17, 2021 Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... May 15, 2024 5 ways cancer can impact sexual wellbeing May 17, 2023 Load more HOT NEWS Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... FDA Approves Second CAR T-Cell Therapy for Lymphoma Can Artificial Intelligence Help See Cancer in New, and Better, Ways? A cut above: Making drug discovery more efficient using CRISPR
